Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:16 AM
Ignite Modification Date:
2025-12-25 @ 3:16 AM
NCT ID:
NCT04833205
Eligibility Criteria:
Inclusion Criteria:
* age 18 years or older, gender not limited;
* A definite diagnosis of Leptomeningeal metastases from lung cancer, including cerebrospinal fluid cytology and/or neuroimaging;
* Have a clear history of lung cancer, including histopathological diagnosis, or cytopathology combined with imaging diagnosis
* Patients who received any of EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib etc.) meet the diagnostic criteria for secondary resistance and were in a slow progression stage
* Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or lung tissue showed positive EGFR expression
* Bone marrow, liver, kidneys and blood clotting function are relatively stable
Exclusion Criteria:
* Eastern Cooperative Oncology Group scored \> 2 points
* Patients had poor compliance, or for other reasons the investigator considered them unsuitable to participate in the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04833205
Study Brief:
Protocol Section:
NCT04833205